Sequencing of the T cell receptor repertoire is a powerful tool for deeper study of immune response, but the unique structure of this type of data makes its meaningful quantification challenging. We introduce a new method, the Gamma-GPD spliced threshold model, to address this difficulty. This biologically interpretable model captures the distribution of the TCR repertoire, demonstrates stability across varying sequencing depths, and permits comparative analysis across any number of sampled individuals. We apply our method to several datasets and obtain interesting biological insights. We have implemented our method in the open-source R package powerTCR. Background 1 Recent advances in high-throughput sequencing of the T cell receptor (TCR) repertoire 2 provide a new, detailed characterization of the immune system. T cells, each displaying 3 a unique TCR, are capable of responding to presented antigens and initiating an 4
. (A) A sample repertoire (gray) of a Sarcoidosis patient and the fitted curves based on the Desponds method (pink) and our method (blue). The Desponds method only fits the data above the threshold it estimates (approximately 15% of the data). Our method fits all of the data. The cross marks the threshold estimated by our method. (B) The QQ-plot of the theoretical fit using our model against the empirical data for the same dataset in (A) shows that our model can achieve a good fit.
Previous research has also identified the imperfectness of the power law behavior for 32 the clone size distribution below some clone size threshold [7, 20] . To handle the 33 imperfectness, [7, 20] proposed to model large clones above the threshold using a type-I 34 Pareto distribution, which is a member of the power-law distribution family, and 35 omitted the clones with frequency below that threshold. The threshold is either 36 user-specified or determined from the data based on a goodness-of-fit measure. Indeed, 37 this model has certain biological basis. Through a stochastic differential equations setup 38 that models the birth, death, selection, and antigen-recognition of cells active in the 39 immune system, Desponds et al. [7] showed that the upper tail of the clone size immune response, such as average T cell lifetime [7] . Yet, the resulting model excludes 44 all clones below a certain frequency threshold. 45 However, even small clones may provide information; for example, Desponds et al. 46 [7] indicated that the generation of new T cells affects the landscape of smaller clone 47 sizes. Other studies have shown that low-frequency clones may support a diverse 48 immune system and present a potential to mobilize against antigens, as in some cases 49 having a clone size distribution highly dominated by a few clones has been correlated 50 with unfavorable clinical outcome [12, 31] . With this in mind, we sought a means to 51 exhaust all available data and consider modeling the complete clone size distribution. 52 To address this question, we propose a novel statistical tool, called powerTCR, to 53 characterize the full distribution of the TCR repertoire. Our method models large clones 54 that are above the threshold, where the power law begins, using the generalized Pareto 55 distribution (GPD), which contains the type-I Pareto distribution as a special case, but 56 provides a more flexible fit. It also models the small clones below the threshold using a 57 truncated Gamma distribution. It determines the threshold in a data-driven manner 58 simultaneously with the characterization of clone size distribution. Our final model 59 contains parameters that are analogous to those found in the type-I Pareto model of 60 
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Desponds et al. [7] , relating our model to the biological interpretation of the dynamics 61 of the immune system. Altogether, this allows our model to more accurately describe 62 the shape of the clone size distribution for both large and small clones. Such a model is 63 well suited for providing a global view of the state of the immune repertoire. It can also 64 be employed to perform comparative analysis of healthy and compromised individuals 65 to identify descriptors of strengths and deficiencies in the immune system.
66

Results
67
The discrete Gamma-GPD spliced threshold model 68 Our goal is to model the clone size distribution of a sample immune repertoire. Figure 69 1A shows a typical distribution plotted using the repertoire of a Sarcoidosis patient in 70 [19] . If the data are truly Pareto distributed, this plot would appear linear [6, 23] .
71
However, noting the linear behavior is only true for the far upper tail of the data, this 72 suggests that these data are a departure from the Pareto distribution. This imperfect 73 power law implicates the use of a heavy-tailed distribution above some threshold and a 74 lighter-tailed distribution below that threshold. Here, we model the tail part with a 75 GPD. The GPD, introduced by [24] , is a classical distribution typically used to model 76 the values in the upper tail of a data set. This formulation results in a distribution with 77 density
where u ∈ (−∞, ∞) is a threshold that typically needs to be prespecified, σ ∈ (0, ∞) 79 is a scale parameter, and ξ ∈ (−∞, ∞) is a shape parameter. The GPD has support 80 x ≥ u when ξ ≥ 0 and u ≤ x ≤ u − σ/ξ when ξ < 0. We model the bulk part with a 81 Gamma distribution with the upper tail truncated at the threshold. The Gamma 82 distribution has a flexible shape and can fit many different clone size distributions. The 83 threshold and the parameters in the two distributions are estimated from the data 84 simultaneously. This setup, where data above and below an unknown threshold are 85 drawn from the "bulk" and "tail" distributions respectively, falls into a class of models 86 called spliced threshold models. The typical motivation for the model is the belief that 87 the data above and below the threshold are driven by different underlying processes. 88 We refer the interested reader to [28] for a thorough review of the general spliced 89 threshold model, and its applications in fields such as insurance, hydrology, and finance. 90 Denote the proportion of data above the threshold u as φ. Let the bulk model 91 distribution function be H c (x|θ b ) and the tail model distribution function be G c (x|θ t ), 92 where subscripts b and t denote the bulk and tail model parameter vectors, respectively. 93 Then the distribution function of the model is given by
with corresponding density
Because the clone size distribution is count data that typically exhibit numerous ties 96 in the less frequently observed clonotypes, it is appropriate to treat this as a discrete 97 3/17 problem. We modify the model in order to account for any quantized or censored data. 98 Let ψ and Ψ be the density and distribution function of a continuous distribution, and 99 let d be the interval length at which the data are censored. We obtain a quantized 100 analog of ψ by letting 101
This results in a discrete model with distribution function
and corresponding probability mass function
where h(x|θ b ) ∼ discrete Gamma(α, β), g(x|θ t ) ∼ discrete GPD(u, σ, ξ), and d = 1, 104 which specifies that we model integer data (see Methods for the functional form of the 105 discrete Gamma distribution and the discrete GPD). This discretization step turns out 106 to be important for accurate estimation in our scenario. See Additional file 1 for a 107 comparison between the performance of the discrete and continuous models in settings 108 resembling true clone size distributions.
109
Biological interpretation of the model 110 The relationship between the discrete Gamma-GPD spliced threshold model and the 111 type-I Pareto model in Desponds et al. [7] , hereafter referred to as the Desponds et al. 112 model, allows us to draw connections between some of our parameters and the dynamics 113 of immune response underpinning their approach. First, results from [7] show that the 114 threshold at which the power law begins is indicative of the point over which a clone's 115 large size can be attributed to active immune response, as opposed to noise in the body 116 that arises from processes such as self-recognition. The threshold fitted from the data 117 provides an objective way to narrow down which clonotypes from a sample repertoire 118 should be interrogated further. This notion is convenient for studying factors such as 119 CDR3 (complementarity-determining region 3) amino acid motifs or specific V, D, and 120 J genes important for combating certain antigens, which are typically determined based 121 on a heuristic abundance cutoff. For example, [30] studies the 1,000 most abundant 122 CDR3 amino acid motifs across all sampled peripheral blood mononuclear cell (PBMC) 123 libraries, while [19] determines CDR3 amino acid motifs from clones that are present 124 with 10 or more reads in a sampled repertoire. The threshold u estimated with our 125 model, however, introduces a means to select motifs that does not rely on heuristics and 126 automatically scales with sequencing depth. consequence of a higher initial concentration of antigens and a higher rate at which new 132 antigens are introduced. Interestingly, ξ also positively correlates with the familiar 133 clonality estimator (1-Pielou's evenness [25] ). Indeed, as ξ increases, the clone size 134 distribution becomes heavier-tailed-that is, more skewed towards dominating clones. 135 
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This trend is in line with that of the clonality estimator, which favors a more uniform 136 clone size distribution as clonality approaches 0 and a distribution dominated by 137 expanded clones as clonality approaches 1. To numerically validate this relationship, we 138 simulated the data from our model and computed the clonality (see Methods). We 139 observed a high correlation between clonality and ξ (Spearman's ρ ≈ 0.9), confirming 140 that ξ reflects the skewness towards dominating clones (see Additional file 2).
141
It is worth noting that our model acquires a theoretical gain via the threshold 142 stability property of the GPD [5] . That is, for any generalized Pareto distributed data, 143 the shape parameter ξ remains constant regardless of changes in u. In our context, this 144 means that at decreasing sequencing depths, though the threshold u would decrease due 145 to fewer cells being sampled, the shape parameter ξ in principle would be stable against 146 the variation in sequencing depth. We will demonstrate this gain in stability on a mouse 147 tumor dataset. See Methods for our extension of the threshold stability property to the 148 case of the discrete GPD.
149
In the following sections, we inspect three different data sets using our model. We Table 1 summarizes the number of unique clonotypes observed and the 164 total number of reads in each sample. The count data used for our analyses is available 165 in Additional file 4. model, respectively. Results from our model support a claim that increased expression 173 of MHC-II induces an increased rate of clonal expansion at the tumor site, as indicated 174 by the uniformly larger estimates of the tail shape parameter ξ in the treatment group. 175 Because the TCR repertoire is often used as an indicator of an individual's immune 176 potency, we next evaluated how well our method discriminates between samples from Euclidean distances between estimates which we then used for hierarchical clustering of 185 the samples. Figure 2 shows that our approach clusters the data by treatment and 186 control groups. This is contrasted against all other methods, which display an incorrect 187 construction of the expected true relationships among the experimental subjects.
188
Our results are robust to variation in sequencing depth 189 One challenge with TCR experiments is that the sequencing depth directly affects the 190 number of TCR variants that are discovered. It is not simple to obtain the same 191 sequencing depth across individuals, and it is also undesirable to discard data in favor of 192 maintaining an equal number of reads across TCR repertoire libraries. An ideal scheme 193 for comparative analysis achieves stable classification across different sequencing depths. 194 We The higher stability of our results is due in part to the threshold stability property 208 of the GPD. It is also attributed to the fact that our method models the full clone size 209 distribution. Doing so circumvents the threshold selection problem encountered when 210 applying the Desponds et al. model, a recurrent issue when fitting models such as the 211 type-I Pareto distribution [29] . For their approach, Desponds et al. select the threshold 212 that minimizes the Kolmogorov-Smirnov statistic [17] , a commonly used goodness-of-fit 213 strategy for fitting a power law distribution [32] . However, the results on this dataset 214 show that this strategy does not always yield stable results across different sequencing 215 depths. cells, which is expected to significantly alter the entire landscape of the TCR repertoire. 222 We applied our method to TCR repertoire data of LS and non-LS Sarcoidosis patients 223 [1] , originally described in [19] . In this study, bronchoscopy with the bronchoalveolar Tables 5 and 6, respectively. We then applied non-metric multidimensional scaling to 231 the distance matrix and plotted the first two coordinates. For the ecological estimators, 232 we simply plotted centered and scaled estimates. As shown in Figure 4A , results from 233 our model cluster LS patients into a tight group distinct from non-LS patients, 234 bolstering the claim that LS patients exhibit a signature immune response. On the 235 other hand, competing methods fail to uncover any pattern ( Figure 4B -C). 236 
216
Differentiation between subtypes of Sarcoidosis patients
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Relationship between the landscape of the clone size 237 distribution and clinical outcome in glioblastoma patients 238 We applied our method to data collected during a clinical trial of 13 glioblastoma 239 patients receiving autologous tumor lysate-pulsed dendritic cell (DC) vaccine therapy 240 [2] , first detailed in [10] . Three intradermal injections were administered to patients at 241 biweekly intervals. TCRβ chains from PBMC samples were sequenced for the patients 242 prior to vaccinations and two weeks following the final injection. Patients were followed 243 up with and their time to progression (TTP) and overall survival (OS) were recorded. 244 TTP was defined as the time from the first DC vaccination until MRI-confirmed tumor 245 progression. OS was calculated as the time from the first DC vaccination until the 246 patient's death from any cause. We investigated whether current tools using TCRs Figure 5A) . 256 This may indicate that the DC therapy alters the landscape of the TCR repertoire into 257 a form that promotes favorable clinical outcome. 258 We do, however, cluster one patient (ID: 33296) with low TTP and OS in the group 259 with overall higher TTP and OS. Interestingly, this misplaced patient had the lowest 260 estimated TIL count and tumor/PBMC overlap of the entire cohort (Additional file 3, 261 Table 7 ). Tumor/PBMC overlap was defined as the total number of reads of shared 262 CDR3s normalized by total reads in the tumor and PBMC samples. Similarly, patient 263 8/17 17232 displayed among the best clinical outcome but clustered with lower-performing 264 patients. Patient 17232 had the highest TIL count and level of tumor/PBMC overlap in 265 the whole cohort. This information taken as a whole suggests that, while the clone size 266 distribution found in blood may indicate something about a patient's response to 267 treatment, it still does not guarantee that T cells will infiltrate the tumor, an important 268 factor for clinical benefit [27] . Additional file 7 highlights the clone size distributions of 269 these two patients against all others.
270
Notably, inferred thresholds (minimum u = 4, maximum u = 6) on this dataset are 271 much lower than on other datasets. This is because this dataset is sequenced less deeply 272 than the others, which consequently reduces the threshold.
273
Noting that clones with size at or above the estimated threshold are considered active 274 participators in the immune response, we sought to investigate whether any relationship 275 existed between clinical outcome and the proportion of more highly stimulated cells. We 276 defined the proportion of highly stimulated cells to be the total number of reads at or 277 above the threshold, normalized by the total number of reads in the entire repertoire 278 (Additional file 3, Table 9 ). We found correlations between this measure and both TTP 279 (Spearman's ρ = 0.54) and OS (Spearman's ρ = 0.80). Rank scatterplots for these 280 correlations are in Figure 5B . The positive correlation we uncovered suggests that this 281 statistic could be a useful tool to quantify the antigen-specificity of the sample.
282
Discussion
283
We have developed a model, the Gamma-GPD spliced threshold model, and 284 demonstrated its utility on several datasets. As shown in our analyses, several 285 biologically relevant descriptive features can be obtained from our model. One is the 286 tail shape parameter ξ, a measure of the weight of the upper tail of the clone size 287 distribution, where a heavier tail of the fitted model implies a more dominated 288 distribution of expanded clones. Another is the proportion of total reads at or above the 289 estimated threshold, a possible measure of intensity of the immune response. The third 290 is the estimated threshold, which is a useful guide to objectively identify CDR3 motifs 291 for downstream analysis. This could involve denoting motifs as only those CDR3s found 292 in TCRs with frequencies at or above the estimated threshold for a given sample, or it 293 could mean studying TCR gene usage among that same group of clonotypes.
294
Similar to other estimators, our model requires that a repertoire be adequately 295 sampled. Without adequate sampling, the differentiating features between TCR 296 repertoires will be masked [7] , and the estimated model parameters will not be reliable. 297 Given the immense diversity of the TCR repertoire, one should in general be cautious 298 about using any method to make inference about a sample TCR repertoire when few 299 cells are sequenced. With sufficient samples, though, the spliced threshold model 300 provides the user a meaningful high-level view of the TCR repertoire.
301
Conclusions
302
The diversity of the TCR repertoire and its responsiveness to stimuli provide a 303 high-dimensional biomarker for monitoring the immune system and its adaptivity.
304
Robust assessment of the clone size distribution through TCR sequencing is important 305 for understanding this diversity. The discrete Gamma-GPD spliced threshold model is a 306 flexible model that effectively captures the shape of the clone size distribution. It is 307 especially appropriate since the heavy-tailed GPD is a good fit to model the highly 308 expanded clones that dominate many TCR repertoire samples. The method also 309 provides a means to comparatively analyze a collection of TCR repertoire samples while 310 9/17 maintaining convenient theoretical properties and interpretations.
311
Compared with existing approaches, our method is more flexible, utilizes the full 312 clone size distribution, is less sensitive to sequencing depth, and identifies the threshold 313 in a data-driven manner. The parameters estimated from our method are biologically 314 relevant and instructive to the dynamics of immune response. Our results on multiple 315 datasets also show that the spliced threshold model is powerful in a range of scenarios 316 for comparing TCR repertoires across samples, revealing potential trends in the 317 landscapes of clone size distributions of affected immune systems. To proceed, we employ a profile likelihood approach. Let u be the threshold, θ b be 329 the bulk parameter vector {α, β}, θ t be the tail parameter vector {σ, ξ}, and θ be the 330 parameter vector {θ b , θ t }. Let also h and H be the density and distribution function of 331 a discrete Gamma distribution, respectively, and let g be the density of a discrete GPD. 332 Then the complete data likelihood is given by
and the profile likelihood of the model at u is denoted as
A grid search over a suitable range of thresholds u = (u 1 , . . . , u k ) may be 335 implemented to maximize the profile likelihood. In this study, we adopted an approach 336 similar to those of [24] and [34] , searching for thresholds at or above the 75% quantile of 337 the sample. The estimated parameters are then where n is the total number of clones and n u denotes the number of clones with size 339 greater than or equal to the threshold.
340
Computation for competing methods
341
The Desponds et al. model was fit as previously described [7] . Briefly, the model has
and distribution function 344
where u > 0 is the threshold and α d > 0 is a shape parameter. For each sample 345 TCR repertoire, a grid of potential thresholds u = (u 1 , . . . , u k ) was constructed by 346 considering every unique clone size in the repertoire. Then, for each u i , the shape 347 parameter is estimated as
where n i is the number of clones with size larger than the threshold u i . Once this value 349 is computed for every threshold in u , the threshold and correspondingα were chosen 350 to minimize the Kolmogorov-Smirnov statistic.
351
The ecological estimators [9, 25] were computed as follows. For a sample X, let 352 S(X) be the sample richness, defined as the number of unique clonotypes in X, and let 353 p i be the number of cells of clonotype i normalized by the total number of cells in the 354 sample. Then, the Shannon entropy of X is
and the clonality of X is The relationship between a pair of TCR repertoires can be elucidated by evaluating the 383 distance between their fitted spliced threshold models. Several methods to compare 384 densities are available. We propose measuring the distance between each pair of 385 distributions using Jensen-Shannon distance (JSD) [16] . This metric is a symmetric and 386 smoothed adaptation of the well-known Kullback-Leibler divergence that does not 387 require the distributions under comparison to share the same support. 388 
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Given discrete distributions P and Q, the JSD between P and Q is 389 JSD(P, Q) = 1 2 i (P i ln
where M i = 1 2 (P i + Q i ). The resulting distances allow analysis and visualization via 390 multidimensional scaling or hierarchical clustering of the samples. Throughout our 391 study, we use Ward's method for hierarchical clustering.
392
Threshold stability of the discrete GPD
393
The threshold stability property of the GPD is well-established [5] . Here, we show that 394 the property also holds for the discrete GPD. Let X ∼ discrete GPD(u, σ, ξ) and denote 395 its distribution function as F with F c as its continuous analog. Then we can write This states that if X ∼ discrete GPD(u, σ, ξ), then 397 X − u ∼ discrete GPD(0, σ + ξ, ξ). Or, for our application, consider a clone size 398 distribution, where clones larger than some threshold u are distributed according to the 399 discrete GPD. At decreasing sequencing depths, this estimated u decreases, implying 400 naturally that the size a clone in the sample must achieve to be considered "expanded" 401 decreases. Still, while u shrinks, the threshold stability property states that ξ remains 402 constant.
403
For each individual, the data are sorted from the count of the most frequently observed clonotype down to the count of the least frequently observed clonotype.
Additional file 5 -Dendrograms for downsampling study
AdditionalFile5.pdf We downsampled mouse tumor data to 80, 60, 40, and 20% of total reads. We used JSD to compute pairwise distances between the samples for our model fits and the Desponds et al. model fits at each downsample level and did hierarchical clustering using Ward's method. The dendrograms for each model at each downsample level are presented here.
Additional file 6 -Clustering of pre-and post-treatment glioblastoma patient samples AdditionalFile6.pdf Clustering dendrograms generated on pre-and post-treatment glioblastoma samples. Groupings presented for the post-treatment samples here correspond to the colored groupings in Figure 5 .
Additional file 7 -Clone size distributions of glioblastoma patients
AdditionalFile7.pdf This plot calls out patients 33296 and 17232 from the glioblastoma patients. Patient 33296 incorrectly clustered with the individuals with favorable clinical outcome, while patient 17232 incorrectly clustered with individuals with unfavorable clinical outcome.
